# EDGAR Filing Document

**Accession Number:** 0002079962
**File Stem:** 0000879169-25-000104
**Filing Date:** 2025-8
**Character Count:** 7658
**Document Hash:** 95cc21e5df8e6e4194a2dc1da16e28b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000879169-25-000104.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0000879169-25-000104

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250721

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mayes Patrick A
- **CENTRAL INDEX KEY:** 0002079962

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12400
- **FILM NUMBER:** 251184807

**MAIL ADDRESS:**
- **STREET 1:** 431 SCHOOL HOUSE LANE
- **CITY:** DEVON
- **STATE:** PA
- **ZIP:** 19333
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INCYTE CORP
- **CENTRAL INDEX KEY:** 0000879169
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943136539
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** 3024986700

**MAIL ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE CORP
- **DATE OF NAME CHANGE:** 20030318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE GENOMICS INC
- **DATE OF NAME CHANGE:** 20000710

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930902

## Ex-24

![](mayes-incytesection16pow001.jpg)

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mayes Patrick A<br><sub>(Last) (First) (Middle)</sub><br>1801 AUGUSTINE CUT-OFF<br><sub>(Street)</sub><br>WILMINGTON, DE 19803<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>INCYTE CORP [ INCY ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-07-21 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP & Chief Scientific Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 67388<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2027-11-06 | Common Stock | 6381 | $105.43 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2028-07-01 | Common Stock | 3148 | $68.62 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2029-01-03 | Common Stock | 9459 | $72.27 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2029-07-01 | Common Stock | 1642 | $85.01 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2030-01-16 | Common Stock | 1643 | $80.50 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2030-07-01 | Common Stock | 2292 | $106.47 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2031-01-14 | Common Stock | 2293 | $90.56 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2031-07-01 | Common Stock | 2263 | $83.58 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2032-01-18 | Common Stock | 2623 | $74.78 | D |  |
| Employee Stock Option (right to buy) | <sup>(3)</sup> | 2032-07-01 | Common Stock | 3055 | $77.67 | D |  |
| Employee Stock Option (right to buy) | <sup>(4)</sup> | 2033-01-19 | Common Stock | 3225 | $83.20 | D |  |
| Employee Stock Option (right to buy) | <sup>(5)</sup> | 2033-07-13 | Common Stock | 3942 | $61.76 | D |  |
| Employee Stock Option (right to buy) | <sup>(6)</sup> | 2034-01-17 | Common Stock | 4246 | $61.18 | D |  |
| Employee Stock Option (right to buy) | <sup>(7)</sup> | 2034-07-14 | Common Stock | 5222 | $64.25 | D |  |
| Employee Stock Option (right to buy) | <sup>(8)</sup> | 2035-01-16 | Common Stock | 4737 | $71.93 | D |  |
| Employee Stock Option (right to buy) | <sup>(9)</sup> | 2035-07-14 | Common Stock | 5846 | $68.25 | D |  |

---

### Footnotes:

(1) This includes:
 3,533 restricted stock units ("RSUs") granted on October 1, 2021 that will vest fully on October 1, 2025; 1,128 RSUs granted on July 2, 2022 that will fully on July 2, 2026; 3,079 RSUs granted on January 20, 2023 that will vest fully on January 20, 2027; 2,820 RSUs granted on July 14, 2023 that will vest 1,140 on July 14, 2026 and July 14, 2027; 5,253 RSUs granted on July 15, 2024 that will vest 1,751 on July 15, 2026, July 15, 2027 and July 15, 2028; 39,783 RSUs granted on June 6, 2025 that will vest fully on June 6, 2028; and 7,795 RSUs granted on July 15, 2025 that will vest 25% annually over four years.

(2) As of July 21st, 2025, the award is fully vested and exercisable

(3) Options granted on July 2, 2022 and will vest monthly through July 2, 2026

(4) Options granted on January 20, 2023 and will vest monthly through July 2, 2026

(5) Options granted on July 14, 2023 and will vest monthly through July 14, 2027

(6) Options granted on January 18, 2024 and will vest monthly through July 14, 2027

(7) Options granted on July 15, 2024 and will vest monthly through July 15, 2028

(8) Options granted on January 17, 2025 and will vest monthly through July 15, 2028

(9) Options granted on July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

**Signature:** /s/ Elizabeth Feeney, Attorney-In-Fact  
**Date:** 2025-08-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**